Pathologic and clinical tumor size discordance in early-stage cervical cancer: Does it matter?


Journal

Gynecologic oncology
ISSN: 1095-6859
Titre abrégé: Gynecol Oncol
Pays: United States
ID NLM: 0365304

Informations de publication

Date de publication:
11 2020
Historique:
received: 16 04 2020
accepted: 05 08 2020
pubmed: 6 9 2020
medline: 10 4 2021
entrez: 5 9 2020
Statut: ppublish

Résumé

The objective of this study was to assess the rate of discordance between clinical and pathologic tumor size for women with stage IB1 cervical cancer (FIGO 2009 criteria), assess risk factors for discordance, and determine the impact of discordance on oncologic outcomes. This was a secondary analysis of a prior multi-institutional retrospective review of patients diagnosed with stage IB1 (FIGO 2009 staging) cervical cancer undergoing radical hysterectomy between 2010 and 2017. Demographic, clinicopathologic, and oncologic data were collected. Pathologic upstaging was defined as having a preoperative diagnosis of stage IB1 cervical cancer with pathology demonstrating a tumor size >4 cm. Demographic and clinicopathologic data was compared using chi-square, fisher exact or 2-sided t-test. Survival was estimated using the Kaplan-Meier method. Of the 630 patients, 77 (12%) were upstaged. Patients who were upstaged had lower rates of preoperative conization (p < .001) or preoperative tumor sizes ≤2 cm (p < .001). Upstaged patients had increased odds of deep stromal invasion, lymphovascular space invasion, positive margins and positive lymph nodes. Almost 88% of upstaged patients received adjuvant therapy compared to 29% of patients with tumors ≤4 cm (odds 18.49, 95% CI 8.99-37.94). Finally, pathologic upstaging was associated with an increased hazard of recurrence (hazard ratio [HR] 1.95, 95% CI 1.03-3.67) and all-cause death (HR 2.31, 95% CI 1.04-5.11). Pathologic upstaging in stage IB1 cervical cancer is relatively common. Upstaging is associated with an 18-fold increased risk of receipt of adjuvant therapy. Patients undergoing preoperative conization and those with tumors <2 cm had lower risks of upstaging. Improvement in preoperative assessment of tumor size may better inform primary treatment decisions.

Identifiants

pubmed: 32888724
pii: S0090-8258(20)33760-4
doi: 10.1016/j.ygyno.2020.08.004
pii:
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

354-358

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors of this manuscript have no conflicts of interest to disclose.

Auteurs

M H Vetter (MH)

The Ohio State University Comprehensive Cancer Center, Columbus, OH, United States.

S Smrz (S)

The Ohio State University Comprehensive Cancer Center, Columbus, OH, United States.

P A Gehrig (PA)

University of North Carolina Gynecologic Oncology, Chapel Hill, NC, United States.

K Peng (K)

Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor, MI, United States.

K Matsuo (K)

University of Southern California Keck School of Medicine, Los Angeles, CA, United States.

B A Davidson (BA)

Duke University, Durham, NC, United States.

M P Cisa (MP)

Duke University, Durham, NC, United States.

B F Lees (BF)

University of Wisconsin, Madison, WI, United States.

L L Brunette (LL)

University of Southern California Keck School of Medicine, Los Angeles, CA, United States.

K Tucker (K)

University of North Carolina Gynecologic Oncology, Chapel Hill, NC, United States.

A Stuart Staley (A)

University of North Carolina Gynecologic Oncology, Chapel Hill, NC, United States.

W H Gotlieb (WH)

McGill University, Montreal, Quebec, Canada.

R W Holloway (RW)

AdventHealth Medical Group GYN Oncology, Orlando, FL, United States.

K G Essel (KG)

University of Oklahoma, Norman, OK, United States.

L L Holman (LL)

University of Oklahoma, Norman, OK, United States.

E Goldfeld (E)

University of Pittsburgh, Pittsburgh, PA, United States.

A Olawaiye (A)

University of Pittsburgh, Pittsburgh, PA, United States.

S Rose (S)

University of Wisconsin, Madison, WI, United States.

S Uppal (S)

Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor, MI, United States.

K Bixel (K)

The Ohio State University Comprehensive Cancer Center, Columbus, OH, United States. Electronic address: Kristin.bixel@osumc.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH